These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38304857)

  • 1. RELAY, Erlotinib Plus Ramucirumab in Untreated,
    Nishino K; Shih JY; Nakagawa K; Reck M; Garon EB; Carlsen M; Matsui T; Visseren-Grul C; Nadal E
    JTO Clin Res Rep; 2024 Feb; 5(2):100624. PubMed ID: 38304857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
    ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
    Nakagawa K; Nadal E; Garon EB; Nishio M; Seto T; Yamamoto N; Park K; Shih JY; Paz-Ares L; Frimodt-Moller B; Zimmermann AH; Wijayawardana S; Visseren-Grul C; Reck M
    Clin Cancer Res; 2021 Oct; 27(19):5258-5271. PubMed ID: 34301751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic
    Nishio K; Seto T; Nishio M; Reck M; Garon EB; Sakai K; Goto K; Kato T; Nakanishi Y; Takahashi T; Yamamoto N; Kiura K; Ohe Y; Tamura T; Visseren-Grul C; Frimodt-Moller B; Hozak RR; Wijayawardana SR; Zimmermann A; Homma G; Enatsu S; Nakagawa K
    JTO Clin Res Rep; 2021 Jun; 2(6):100171. PubMed ID: 34590023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
    Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
    Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with
    Nishio K; Sakai K; Nishio M; Seto T; Visseren-Grul C; Carlsen M; Matsui T; Enatsu S; Nakagawa K
    Transl Lung Cancer Res; 2023 Aug; 12(8):1702-1716. PubMed ID: 37691865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
    Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
    Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
    Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
    Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
    Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
    Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
    Chiu CH; Lin MC; Wei YF; Chang GC; Su WC; Hsia TC; Su J; Wang AK; Jen MH; Puri T; Shih JY
    Target Oncol; 2023 Jul; 18(4):505-515. PubMed ID: 37329423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
    Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
    Grant MJ; Aredo JV; Starrett JH; Stockhammer P; van Alderwerelt van Rosenburgh IK; Wurtz A; Piper-Valillo AJ; Piotrowska Z; Falcon C; Yu HA; Aggarwal C; Scholes D; Patil T; Nguyen C; Phadke M; Li FY; Neal J; Lemmon MA; Walther Z; Politi K; Goldberg SB
    Clin Cancer Res; 2023 Jun; 29(11):2123-2130. PubMed ID: 36913537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With
    Nishio M; Nishio K; Reck M; Garon EB; Imamura F; Kawaguchi T; Yamaguchi H; Ikeda S; Hirano K; Visseren-Grul C; Ceccarelli M; Wijayawardana SR; Zimmermann A; Matsui T; Enatsu S; Nakagawa K
    JTO Clin Res Rep; 2022 Apr; 3(4):100303. PubMed ID: 35369607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
    Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K;
    Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.
    Gu Y; Yu J; Hu H; Zhang H; Cao B; Liang L
    Thorac Cancer; 2023 Nov; 14(31):3147-3160. PubMed ID: 37704565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT; Zhang SL; Han CB; Ma JT
    Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
    Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced
    Chen F; Chen N; Yu Y; Cui J
    Front Oncol; 2020; 10():904. PubMed ID: 32714857
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
    Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
    Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.